Back |
home / stock / aker / aker message board
Subject | By | Source | When |
---|---|---|---|
Since MyMD has not yet announced any | knuts4oe | investorshub | 03/16/2021 1:11:35 AM |
Jonnie must have a passion for breeding rabbits | leifsmith | investorshub | 03/15/2021 2:56:42 PM |
Looks like all these companies have as their | knuts4oe | investorshub | 03/15/2021 2:15:17 PM |
Here is yet another new FL company whose | knuts4oe | investorshub | 03/15/2021 1:55:57 PM |
knuts4oe, grateful for your research - substantial findings | leifsmith | investorshub | 03/15/2021 1:21:51 PM |
That's fascinating. Thanks! | leifsmith | investorshub | 03/15/2021 1:08:10 PM |
Everyone seen this - | knuts4oe | investorshub | 03/15/2021 1:06:31 AM |
OOPS! | knuts4oe | investorshub | 03/13/2021 5:17:26 PM |
At the risk of repetition just noticed that | knuts4oe | investorshub | 03/13/2021 5:13:19 PM |
While we can rule out Covid-19 as the | knuts4oe | investorshub | 03/12/2021 10:24:26 PM |
As you know, the company never said it | leifsmith | investorshub | 03/12/2021 6:41:18 PM |
$AKER The reverse merger with MYMD paper | SeanVan | investorshub | 03/11/2021 6:50:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Akers Biosciences Inc. Company Name:
AKER Stock Symbol:
NASDAQ Market:
Akers Biosciences Inc. Website:
FORT WORTH, Texas, April 29, 2021 (GLOBE NEWSWIRE) -- Contango Oil & Gas Company (NYSE American: MCF) (“Contango” or the “Company”) today announced the appointment of Karen Simon and Janet Pasque to its Board of Directors (the “Board”) effective...
Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol " MYMD " Upon Closing, the Combined Company will focus on developing and commercializing novel immunotherapy pipeline assets, including its lead molecule MYMD-1 ...
Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement...